Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health’s (RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement with telehealth company Homify
- Homify was founded last year and plans to launch with ResApp’s smartphone-based acute respiratory diagnostic test, ResAppDx, as a foundational diagnostic support tool
- The parties have signed a letter of intent agreement which is conditional on Homify being approved to operate a telehealth business in the Philippines
- ResApp will also need regulatory approval for the test as a medical device in the Philippines before the launch can take place
- Shares are up 1.67 per cent at 6.1 cents at 3.45pm AEDT
Digital health company ResApp Health’s (RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement with local telehealth start-up Homify.
Based in the Philippines, Homify uses a smartphone as a clinical device that offers various healthcare services. In particular it allows patients to measure vital signs and offers online consultations, direct medical prescriptions and constant home monitoring.
The company was founded last year and plans to launch with ResApp’s smartphone-based acute respiratory diagnostic test, ResAppDx, as a foundational diagnostic support tool for its telehealth services.
ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s inbuilt microphone. It is CE Marked in Europe and TGA approved for Australian Register of Therapeutic Goods listing in Australia.
The parties have signed a non-exclusive, three-year binding letter of intent agreement which is conditional on Homify achieving certain milestones, including securing the regulatory and legal approvals to operate a telehealth business in the Philippines.
ResApp will also need to obtain regulatory approval for the test as a medical device in the Philippines before the launch can take place.
If given the green light, Homify plans to launch ResAppDx on its platform in the middle of this calendar year.
In assessing ResApp’s technology, Homify CEO Wilson Uy said the company was “very impressed” and was excited to have ResAppDx as a foundational diagnostics partner for its telehealth platform.
“We believe the ResAppDx test will provide great benefits for Filipino patients and clinicians and provide a significant point of difference for the Homify telehealth proposition.”
ResApp shares were up 1.67 per cent at 6.1 cents at 3:45pm AEDT.
